Patents Examined by James H. Alstrum-Acevedo
  • Patent number: 11413322
    Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: August 16, 2022
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • Patent number: 11407796
    Abstract: The present invention relates to a new peptide called Antisecretory Factor (AF) 17 which is an isolated recombinant and/or synthetically produced which has a t½ of at least 1.8 h. The peptide is e.g. useful for normalizing pathological fluid transport and/or inflammatory reactions in animals and in humans. AF-17 and pharmaceutical compositions of AF-17 can e.g. be used for treating and/or preventing TBI and/or secondary brain injuries associated with TBI, as well as for treating and/or preventing acquired brain injuries and to optimize cancer treatment.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: August 9, 2022
    Assignee: LANTMÄNNEN AS-FAKTOR AB
    Inventor: Stefan Lange
  • Patent number: 11357824
    Abstract: Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: June 14, 2022
    Assignee: Axcella Health Inc.
    Inventors: Michael Hamill, Brett Boghigian, Caitlyn Harvey, David Berry, David Young, Geoffrey Von Maltzahn, John Kramarczyk, Jameson Rogers, Kathryn Heard, Michael Doherty, Nathaniel Silver, Phillip Samayoa, Subhayu Basu, Shaila Rahman, Vimal Vaidya, Ying-Ja Chen
  • Patent number: 11319345
    Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: May 3, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto
  • Patent number: 11306128
    Abstract: Methods of purifying mucin, purified mucin, and products comprising the purified mucin. The methods include combining a mucin-containing substance with water and one or more purification agents to form a purification mixture, incubating the purification mixture for a time sufficient to form a mucin precipitate in a liquid phase, and separating the mucin precipitate from the liquid phase. The purification agents include one or more of a surfactant, a chelating agent, and a protic solvent. The mucin purified from the methods can be used alone or in combination with a biopolymer such as a tannin and chitosan and can be used to generate materials in the form of a gel, a foam, a film, or a powder.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: April 19, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jess Dreher Reed, Sergio Madrigal-Carballo, Michael Allen Polewski, Christian Gerald Krueger, Emilia Alfaro-Viquez
  • Patent number: 11304990
    Abstract: The present invention provides a method of treating intracellular infections, in particular intracellular bacterial, fungal, and protozoal infections.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 19, 2022
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • Patent number: 11298402
    Abstract: Methods for modulating lysosome-mediated microautophagy of a lipid or protein substrate in a cell are provided herein. In certain embodiments, said methods may comprise increasing lysosome-mediated microautophagy by treating the cell with a microautophagy-enhancing agent which increases lysosomal association-dissociation events between lysosomes and the cellular lipid or protein substrate and/or increases lysosomal degradation capacity; or decreasing lysosome-mediated microautophagy by treating the cell with a microautophagy-reducing agent which reduces lysosomal association-dissociation events between lysosomes and the cellular lipid or protein substrate and/or decreases lysosomal degradation capacity; thereby modulating lysosome-mediated microautophagy of the lipid or protein substrate.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: April 12, 2022
    Assignee: University of Ottawa
    Inventors: Mohsen Amir Alipour, Zemin Yao
  • Patent number: 11298397
    Abstract: [Problem] To provide a composition for hemostasis that can be applied uniformly to a bleeding site and exerts a high hemostatic effect. [Solution] Provided is a composition to be applied to the subject as a spray, wherein the composition is characterized in that the spray is for hemostasis, and the composition includes a self-assembling peptide, the self-assembling peptide gelling due to self-assembly when the composition is applied to the bleeding site of the subject, and the self-assembling peptide being included in the composition in a concentration having an improved hemostatic capacity in comparison to direct application.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: April 12, 2022
    Assignee: 3-D Matrix, Ltd.
    Inventors: Keiji Nagano, Satoru Kobayashi
  • Patent number: 11291626
    Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: April 5, 2022
    Assignee: OptiNose AS
    Inventor: Per Gisle Djupesland
  • Patent number: 11285192
    Abstract: The present specification provides compositions of ?-endorphin and adrenocorticotropic hormone (ACTH). These compositions are useful in methods of treating disease.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: March 29, 2022
    Assignee: Adamis Pharmaceuticals Corporation
    Inventors: Charles Peter Lollo, Dennis J. Carlo
  • Patent number: 11267859
    Abstract: The present invention provides novel GM-CSF constructs and methods of using the same. In certain embodiments, the constructs of the invention comprise certain peptide fragments from GM-CSF. In other embodiments, the invention provides certain GM-CSF peptides that act as GM-CSF mimetics.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: March 8, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Huntington Potter, Glenn Simon
  • Patent number: 11260133
    Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: March 1, 2022
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara
  • Patent number: 11261221
    Abstract: The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making CD137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 1, 2022
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Marlon Hinner, Christine Rothe, Shane Olwill, Andrea Allersdorfer, Rachida Siham Bel Aiba
  • Patent number: 11261215
    Abstract: The present invention provides prodrugs of somatostatin peptide and peptide analogs that are tissue permeable and oral bioavailable and enable activity of the somatostatin analog at the circulation or target tissue after cleavage of charge-masking lipophilic moieties. Pharmaceutical compositions comprising these prodrugs and their use in therapy and diagnosis are also provided.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 1, 2022
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Amnon Hoffman, Chaim Gilon, Adi Klinger, Johnny Naoum
  • Patent number: 11253629
    Abstract: A bone gel composition consists of cortical bone. The cortical bone is made from cut pieces freeze-dried then ground into particles and demineralized then freeze-dried. A volume of the particles is placed in a solution of sterile water to create a mixture, the water volume being at least twice the particle volume, the mixture is autoclaved under heat and pressure to form a gelatin, the resulting bone gel is formed into sheets having a thickness (t).
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: February 22, 2022
    Assignee: Vivex Biologics Group, Inc.
    Inventors: Wendy W. Weston, Silvia Daniela Gonzales, Edgar S. Maldonado
  • Patent number: 11246912
    Abstract: The present invention is directed to a method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an adropin stimulating agent. Further provided are a method and a kit for diagnosing or prognosing liver metastases in a subject.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: February 15, 2022
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Rinat Abramovitch, Esther Goldlist
  • Patent number: 11241487
    Abstract: Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: February 8, 2022
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Henry Daniell, Qiuhong Li, Mohan K. Raizada
  • Patent number: 11235033
    Abstract: The subject invention provides molecules, compositions and methods for treating, preventing or ameliorating vascular calcification, for example, medial vascular calcification or intimal atherosclerotic calcification. The subject invention also provides molecules, compositions and methods for treating or preventing a disease associated with vascular calcification. The methods of the subject invention employ relaxin-based and/or epidermal growth factor receptor (EGFR)-based strategies through the use of RXFP1 agonists and/or EGFR inhibitors.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 1, 2022
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Joshua Hutcheson, Alexander Agoulnik, Hooi Hooi Ng
  • Patent number: 11230581
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: January 25, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11230576
    Abstract: The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: January 25, 2022
    Assignee: Navigo Proteins GmbH
    Inventors: Paul Knick, Erik Fiedler, Ulrich Haupts, Maren Meysing